PAREXEL International Corporation (PRXL) Receives Price Target

PAREXEL International Corporation (PRXL) stock is expected to deviate a maximum of $10.11 from the average target price of $70.21 for the short term period. 7 Street Experts have initiated coverage on the stock with the most promising target being $80 and the most muted being $49.

PAREXEL International Corporation (PRXL) : Zacks Investment Research ranks PAREXEL International Corporation (PRXL) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 12 research analysts is 2.33, which indicates as a Buy.


Also, Citigroup maintains their rating on the shares of PAREXEL International Corporation (NASDAQ:PRXL). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $80 per share from $74 per share. The rating by the firm was issued on August 5, 2016.

PAREXEL International Corporation (NASDAQ:PRXL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $68.00 and $67.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $68.59. The buying momentum continued till the end and the stock did not give up its gains. It closed at $68.34, notching a gain of 0.46% for the day. The total traded volume was 279,468 . The stock had closed at $68.03 on the previous day.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services, PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management, data management, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, medical imaging services, electronic data capture systems, clinical trial management systems, Web-based portals, and other product development tools and services.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *